NCT00005779View on ClinicalTrials.gov

Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 2004

Conditions
HIV Infections
Interventions
DRUG

Interleukin-12

BIOLOGICAL

HIV-1 C4-V3 Polyvalent Peptide Vaccine

Trial Locations (3)

27710

Duke Univ Med Ctr, Durham

60612

Rush Presbyterian - Saint Luke's Med Ctr, Chicago

775550435

Univ of Texas Galveston, Galveston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH